The new PDUFA review model might be changed mid-stream based on data compiled by the industry trade groups who helped create it.
The showcase provision of the 2012 prescription drug user fee act reauthorization extends new molecular entity NDA and BLA application reviews two months and creates mid- and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?